Drugs / MTX
last change May 2019 re-read 9 days ago

MTX

Developed for
rheumatoid arthritis
Investigated by
Gilead Sciences · Lakefront Biotherapeutics NV

Trials 1

20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02886728 Aug 2016 → Oct 2018 rheumatoid arthritis Gilead Sciences Completed Met primary

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MTX ClinicalTrials.gov intervention name — accepted as the source's own label NCT02886728 ↗